CZL-105
CZL-105 is a highly potent, selective, and orally active p300/CBP inhibitor, with IC50 values of 0.09 μM and 0.08 μM against p300 and CBP bromodomains, respectively. CZL-105 inhibits the proliferation of OPM-2 multiple myeloma cells with an IC50 of 57 nM, and induces G0/G1 cell cycle arrest and apoptosis. CZL-105 is applicable for research related to multiple myeloma.
For research use only. We do not sell to patients.
- CAS No.: 3094841-98-9
- Formula: C31H36FN5O4
- Molecular Weight:561.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CBP 0.08 μM (IC50, AlphaScreen) |
p300 0.09 μM (IC50, AlphaScreen) |
p300 11.8 nM (IC50, AlphaLISA) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| OPM-2 | IC50 |
57 nM
|
Inhibited cell proliferation.
Inhibited cell proliferation.
|
acs.jmedchem.5c03730 |
In Vitro
CZL-105 potently inhibits purified human p300 bromodomain with an IC50 of 11.8 nM[1].
CZL-105 (up to 1 μM) potently inhibits purified human p300 and CBP bromodomains with IC50 values of 0.09 μM and 0.08 μM, respectively, and shows no activity against BET bromodomains at concentrations up to 1 μM[1].
CZL-105 (200 μM; 30 min) is a selective binder to purified human p300 and CBP bromodomains, with ΔTm values of 15.25 °C and 14.5 °C respectively, and does not stabilize other tested non-BET bromodomains[1].
CZL-105 (1 μM; 0, 7, 17, 30, 60 min) has favorable metabolic stability in mouse liver microsomes, with a half-life of 88.5 min[1].
CZL-105 (gradient concentrations; 6 days) potently inhibits the proliferation of OPM-2 multiple myeloma cells with an IC50 of 57 nM[1].
CZL-105 (250-500 nM; 3 days) induces G0/G1 phase arrest in OPM-2 multiple myeloma cells in a dose-dependent manner after 3 days of treatment[1].
CZL-105 (250-500 nM; 1-3 days) induces apoptosis in OPM-2 multiple myeloma cells in both time- and dose-dependent manners, as evidenced by flow cytometry and activation of apoptosis-related proteins[1].
CZL-105 (3 days) increases lipid ROS levels in OPM-2 multiple myeloma cells in a dose-dependent manner, but cell death induced by CZL-105 is not primarily mediated by the canonical ferroptosis pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:OPM-2 multiple myeloma cells
-
Concentration:gradient concentrations
-
Incubation Time:6 days
-
Result:Potently inhibited OPM-2 cell proliferation with an IC50 of 57 nM.
-
Cell Line:OPM-2 multiple myeloma cells
-
Concentration:250, 500 nM
-
Incubation Time:3 days
-
Result:Induced a dose-dependent increase in the percentage of cells in the G0/G1 phase.
Caused significant G0/G1 arrest observed at both tested concentrations relative to vehicle control.
-
Cell Line:OPM-2 multiple myeloma cells
-
Concentration:250-500 nM (3-day incubation); 500 nM (1, 2, 3-day incubations)
-
Incubation Time:1-3 days
-
Result:Induced apoptosis in a dose-dependent manner after 3 days (13% apoptotic cells with vehicle, 49% with 250 nM, 71% with 500 nM).
Induced apoptosis in a time-dependent manner at 500 nM (13% at 1 day, 32% at 2 days, 71% at 3 days).
Increased levels of cleaved caspase-3 and cleaved PARP, with slight decreases in pro-caspase-3 and full-length PARP, at 250 nM and 500 nM after 3 days of treatment.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t |
|---|---|---|---|---|---|---|
| Mice[1] | 25 mg/kg | p.o. | 1.53 h | 0.25 h | 2163 ng/mL | 1358 ng·h/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude/nude mice[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; once daily; 12 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 61%.
Showed no mortality or body weight loss during the treatment period.
Chemical Information
-
CAS No. 3094841-98-9
-
Molecular Weight 561.65
-
Formula C31H36FN5O4
-
SMILES
CC1=C(C(C)=NO1)C2=CC3=NC([C@H]4N(C(CCC4)=O)C5=CC(F)=C(C=C5)OC)=C(N3C=C2)N[C@H]6CC[C@@H](CC6)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)